Impact of type of dialyzable beta-blockers on subsequent risk of mortality in patients receiving dialysis: A systematic review and meta-analysis

CNU IR > Pharmacy and Science > Dept. of Health and Nutrition (including master's program) > Periodical Articles > Item 310902800/34687

Please use this identifier to cite or link to this item: https://ir.cnu.edu.tw/handle/310902800/34687

Title:	Impact of type of dialyzable beta-blockers on subsequent risk of mortality in patients receiving dialysis: A systematic review and meta-analysis
Authors:	Yeh, Tzu-Hsuan Tu, Kuan-Chieh Hung, Kuo-Chuan Chuang, Min-Hsiang Chen, Jui-Yi
Contributors:	Chi Mei Hospital Department of Health and Nutrition, Chia Nan University of Pharmacy & Science
Keywords:	pharmacokinetics atenolol carvedilol hemodialysis hypertension metoprolol blockade failure events
Date:	2022
Issue Date:	2023-12-11 14:05:11 (UTC+8)
Publisher:	PUBLIC LIBRARY SCIENCE
Abstract:	Background Beta-blockers has been reported to improve all-cause mortality and cardiovascular mortality in patients receiving dialysis, but type of beta-blockers (i.e., high vs. low dialyzable) on patient outcomes remains unknown. This study aimed at assessing the outcomes of patients receiving dialyzable beta-blockers (DBBs) compared to those receiving non-dialyzable beta-blockers (NDBBs). Methods We searched the databases including PubMed, Embase, Cochrane, and ClinicalTrials. gov until 28 February 2022 to identify articles investigating the impact of DBBs/NDBBs among patients with renal failure receiving hemodialysis/peritoneal dialysis (HD/PD). The primary outcome was risks of all-cause mortality, while the secondary outcomes included risk of overall major adverse cardiac event (MACE), acute myocardial infarction (AMI) and heart failure (HF). We rated the certainty of evidence (COE) by Cochrane methods and the GRADE approach. Results Analysis of four observational studies including 75,193 individuals undergoing dialysis in hospital and community settings after a follow-up from 180 days to six years showed an overall all-cause mortality rate of 11.56% (DBBs and NDBBs: 12.32% and 10.7%, respectively) without significant differences in risks of mortality between the two groups [random effect, aHR 0.91 (95% CI, 0.81-1.02), p = 0.11], overall MACE [OR 1.03 (95% CI, 0.781.38), p = 0.82], and AMI [OR 1.02 (95% CI, 0.94-1.1), p = 0.66]. Nevertheless, the pooled odds ratio of HF among patients receiving DBBs was lower than those receiving NDBB [random effect, OR 0.87 (95% CI, 0.82-0.93), p<0.001]. The COE was considered low for overall MACE, AMI and HF, while it was deemed moderate for all-cause mortality. Conclusions The use of dialyzable and non-dialyzable beta-blockers had no impact on the risk of allcause mortality, overall MACE, and AMI among dialysis patients. However, DBBs were associated with significant reduction in risk of HF compared with NDBBs. The limited number of available studies warranted further large-scale clinical investigations to support our findings.
Relation:	PLOS ONE, v.17, n.12, e0279680
Appears in Collections:	[Dept. of Health and Nutrition (including master's program)] Periodical Articles

Files in This Item:

File	Description	Size	Format
index.html		0Kb	HTML	303	View/Open
journal.pone.0279680.pdf		1038Kb	Adobe PDF	41	View/Open

Loading...